This legislation seeks to significantly improve access to affordable, evidence-based opioid treatments and recovery support services across various healthcare programs. It mandates the Center for Medicare and Medicaid Innovation to establish a new model in 15 selected states, which will eliminate coinsurance, copayments, and deductibles for Medicare beneficiaries receiving opioid use disorder (OUD) treatments, overdose reversal medications, behavioral health services, and community-based recovery support services. These states will be chosen based on criteria such as a high proportion of Medicare beneficiaries, high opioid overdose death rates, and significant rural populations. Furthermore, the bill requires group health plans and health insurance issuers to provide coverage for specific opioid treatments without imposing any cost-sharing requirements. This includes prescription drugs for OUD treatment or overdose reversal, behavioral health services for OUD (including non-hospital residential facilities), and community recovery support services like peer counseling and transportation when provided in conjunction with medication-assisted treatment. These provisions are set to take effect for plan years beginning on or after January 1, 2027. Finally, the bill strengthens Medicaid's role in addressing the opioid crisis by increasing the Federal Medical Assistance Percentage (FMAP) to 90% for state expenditures on medication-assisted treatment (MAT). It also provides states with the option to include recovery support services, such as peer counseling and transportation, as part of their covered MAT services, further supporting individuals in maintaining a healthy lifestyle after opioid misuse treatment.